SCHEMBL5072032

SCHEMBL5072032

CC(C)(C)c1cc(C[S])cc(C(C)(C)C)c1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.59
GAA P10253 6/20 0.59
TSHR P16473 4/20 0.59
LMNA P02545 3/20 0.59
MAPK1 P28482 3/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
CYP1A2 P05177 2/20 0.57
CYP3A4 P08684 2/20 0.57
BLM P54132 2/20 0.57
ATM Q13315 2/20 0.57
HIF1A Q16665 2/20 0.57
NPSR1 Q6W5P4 2/20 0.57
ALOX15 P16050 2/20 0.57
GMNN O75496 1/20 0.57
GABBR2 O75899 1/20 0.57
TP53 P04637 1/20 0.57
CYP2C9 P11712 1/20 0.57
NFKB1 P19838 1/20 0.57
CYP2C19 P33261 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9850923 0.88 CYP2C9 (0.57) ALDH1A1GAATSHRLMNAMAPK1
SCHEMBL5610697 0.83 ALDH1A1 (0.55) ALDH1A1GAATSHRLMNAMAPK1
SCHEMBL4447310 0.82 ALDH1A1 (0.59) ALDH1A1GAATSHRLMNAMAPK1
SCHEMBL39559 0.81 ALDH1A1 (0.63) ALDH1A1GAATSHRLMNAMAPK1
SCHEMBL284696 0.81 ALDH1A1 (0.63) ALDH1A1GAATSHRLMNAMAPK1
SCHEMBL39434 0.79 HSPA5 (0.74) ALDH1A1GAATSHRLMNAMAPK1
SCHEMBL42656 0.79 ALDH1A1 (0.64) ALDH1A1GAATSHRLMNAMAPK1
SCHEMBL526641 0.79 ALDH1A1 (0.61) ALDH1A1GAATSHRLMNAMAPK1
SCHEMBL5609403 0.78 ALDH1A1 (0.50) ALDH1A1GAATSHRLMNAMAPK1
SCHEMBL10719480 0.77 ALDH1A1 (0.59) ALDH1A1GAATSHRLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1885533-A2 METHOD FOR IMPREGNATING LIGNOCELLULOSIC MATERIALS WITH EFFECT AGENTS BASF AKTIENGESELLSCHAFT (DE) 2008-02-13 EP disclosed
US-7199139-B2 Medicinal compositions containing diuretic and insulin resistance-improving agent SANKYO COMPANY, LIMITED (JP) 2007-04-03 US disclosed
WO-2006117162-A2 METHOD FOR IMPREGNATING LIGNOCELLULOSIC MATERIALS WITH EFFECT AGENTS BASF AKTIENGESELLSCHAFT (DE) 2006-11-09 WO disclosed
EP-1354602-B1 MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT SANKYO CO (JP) 2006-10-04 EP disclosed
EP-1695716-A2 Medicinal compositions containing diuretics and insulin sensitizers Sankyo Company, Limited (JP) 2006-08-30 EP disclosed
US-20050288339-A1 Medicinal compositions containing diuretic and insulin resistance-improving agent SANKYO COMPANY, LIMITED (JP) 2005-12-29 US disclosed
EP-1529830-A1 Ashless additive formulations suitable for hydraulic oil applications Chevron Oronite S.A. (FR) 2005-05-11 EP disclosed
US-20050096236-A1 Ashless additive formulations suitable for hydraulic oil applications CHEVRON ORONITE S.A. 2005-05-05 US disclosed
EP-1451275-A4 SULFUR CONTAINING LUBRICATING OIL ADDITIVE SYSTEM PARTICULARLY USEFUL FOR NATURAL GAS FUELED ENGINES CHEVRON ORONITE CO (US) 2005-03-16 EP disclosed
EP-1451275-A1 SULFUR CONTAINING LUBRICATING OIL ADDITIVE SYSTEM PARTICULARLY USEFUL FOR NATURAL GAS FUELED ENGINES Chevron Oronite Company LLC (US) 2004-09-01 EP disclosed
EP-0290391-A2 Polyolefines stabilized against light degradation CIBA-GEIGY AG (CH) 1988-11-09 EP disclosed
EP-0253773-A2 Stabilized synthetic polymer CIBA-GEIGY AG (CH) 1988-01-20 EP disclosed
EP-0252877-A1 Synergistic stabilizing mixture CIBA-GEIGY AG (CH) 1988-01-13 EP disclosed
EP-0252003-A2 Substituted aminoxy succinates and their application as stabilisers CIBA-GEIGY AG (CH) 1988-01-07 EP disclosed
EP-0249577-A2 Long chain-(4-hydroxyphenyl)propionate derivatives as stabilizers CIBA-GEIGY AG (CH) 1987-12-16 EP disclosed
EP-0244362-A2 Compositions stabilized by aminoxysilanes CIBA-GEIGY AG (CH) 1987-11-04 EP disclosed
EP-0244355-A2 Compositions stabilized with substituted aminocarbamates, and substituted aminocarbamates CIBA-GEIGY AG (CH) 1987-11-04 EP disclosed
EP-0241427-A2 Compositions stabilised with di- or trisubstituted hydroxylamines and new di- or trisubstituted hydroylamines CIBA-GEIGY AG (CH) 1987-10-14 EP disclosed
EP-0240463-A2 Substituted aminooxypropion amides CIBA-GEIGY AG (CH) 1987-10-07 EP disclosed
EP-0228994-A1 Substituted aminoxyethylsulfoxides and -sulfones CIBA-GEIGY AG (CH) 1987-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288339-A1 Medicinal compositions containing diuretic and insulin resistance-improving agent GPR119, INSR, IRS1 ALDH1A1 2128/4885GAA 818/4885TSHR 899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.